CA
AVBP icon

Clearstead Advisors’s ArriVent BioPharma AVBP Stock Holding History

Clearstead Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139 Buy
+4
New +$118 ﹤0.01% 3288
2025
Q4 		– Sell
-1
Closed -$19 – 3302
2025
Q3 		$19 Hold
1
– – ﹤0.01% 3025
2025
Q2 		$22 Buy
+1
New +$21 ﹤0.01% 2707

Other funds holding AVBP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

Clearstead Advisors's AVBP Position: Q2 2026 in Review

Clearstead Advisors opened a new position in ArriVent BioPharma (AVBP) in Q2 2026: 4 shares worth $139. The stake represents ﹤0.01% of the portfolio and ranks #3288 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in AVBP as recently as Q3 2025.

Clearstead Advisors first reported a position in AVBP in Q2 2025 and has held it in 3 quarters since. 41 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Clearstead Advisors held 4 shares of ArriVent BioPharma worth $139 as of Q2 2026.
  • ArriVent BioPharma was a new Clearstead Advisors position in Q2 2026.
  • ArriVent BioPharma made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3288 holding.
  • Clearstead Advisors first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 3 quarters since.
  • 41 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.